SpringWorks Faces Market Volatility Amid Insider Selling SpringWorks Therapeutics' stock has experienced fluctuations, with shares down 6% recently. Insider selling activity, including the CEO's sale of 49,000 shares, has raised questions. Analysts remain positive, with consensus price targets averaging $73.20. However, the company continues to face challenges in balancing revenue growth with ongoing R&D investments.34